Jina Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Nov 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Endoxifen methods and compositions for inhibition of protein kinase C (US 11,672,758) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Feb 13, 2027The maintenance fee for Endoxifen compositions and methods (US 10,376,479) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 1 fee due Nov 10, 2027The maintenance fee for Endoxifen compositions and methods (US 9,333,190) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,376,479 | Endoxifen compositions and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 11,672,758 | Endoxifen methods and compositions for inhibition of protein kinase C In force · From the USPTO record | In force | From the USPTO record | |
| US 9,333,190 | Endoxifen compositions and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 9,750,812 | Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,637,515 | Guggulphospholipid methods and compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 11,389,413 | Methods of Preparing Compositions Containing Thymoquinone In force · High confidence | In force | High confidence | |
| US 11,291,640 | Endoxifen for the treatment of bipolar I disorder In force · From the USPTO record | In force | From the USPTO record | |
| US 12,245,997 | Endoxifen for the Treatment of Bipolar I Disorder In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 1 abandoned · 7 no status recorded